Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)70124-5 ◽

2015 ◽

Vol 16 (5) ◽

pp. 583-594 ◽

Cited By ~ 239

Author(s):

Jean-Pascal H Machiels ◽

Robert I Haddad ◽

Jérôme Fayette ◽

Lisa F Licitra ◽

Makoto Tahara ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

Second Line ◽

Open Label ◽

Phase 3 ◽

Head Neck

PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Head & Neck ◽

10.1002/hed.24311 ◽

2015 ◽

Vol 38 (S1) ◽

pp. E1756-E1761 ◽

Cited By ~ 10

Author(s):

Danny Rischin ◽

David R. Spigel ◽

Douglas Adkins ◽

Richard Wein ◽

Susanne Arnold ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

Second Line ◽

Phase 2 ◽

Phase 2 Trial ◽

Faculty Opinions recommendation of Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734912521.793555705 ◽

2019 ◽

Author(s):

Ricardo Hitt

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Second Line ◽

Observational study of the cetuximab relative dose intensity (RDI) in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Data on the maintenance and every two weeks use (DIRECT study)

Annals of Oncology ◽

10.1093/annonc/mdw376.19 ◽

2016 ◽

Vol 27 ◽

pp. vi334 ◽

Cited By ~ 2

Author(s):

J. Guigay ◽

E. Chamorey ◽

P. Céruse ◽

F. Mornex ◽

M. Degardin ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Observational Study ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Dose Intensity ◽

Line Treatment ◽

First Line ◽

Afatinib Versus Methotrexate (Mtx) As Second-Line Treatment for Patients with Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (Hnscc) Who Progressed After Platinum-Based Therapy: Primary Efficacy Results of Lux-Head & Neck 1, a Phase III Trial

Annals of Oncology ◽

10.1093/annonc/mdu438.30 ◽

2014 ◽

Vol 25 ◽

pp. v1 ◽

Cited By ~ 3

Author(s):

J-P. Machiels ◽

R.I. Haddad ◽

J. Fayette ◽

L.F. Licitra ◽

M. Tahara ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Primary Efficacy ◽

Phase Iii Trial ◽

Head Neck

First-line versus second-line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck

Annals of Oncology ◽

10.1093/annonc/mdz252.030 ◽

2019 ◽

Vol 30 ◽

pp. v462

Author(s):

C. Even ◽

N. Torossian ◽

T. Ibrahim ◽

N. Martin ◽

L. Mayache Badis ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Second Line ◽

First Line ◽

Methotrexate, Vinblastine, Epidoxorubicin, and Bleomycin as Second-Line Chemotherapy for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

ORL ◽

10.1159/000276674 ◽

1994 ◽

Vol 56 (5) ◽

pp. 279-282 ◽

Cited By ~ 5

Author(s):

Vittorio Gebbia ◽

Roberto Valenza ◽

Antonio Testa ◽

Nicolò Borsellino ◽

Giuseppe Cannata ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Second Line ◽

Second Line Chemotherapy ◽

Line Chemotherapy

123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial

Annals of Oncology ◽

10.1016/j.annonc.2021.10.142 ◽

2021 ◽

Vol 32 ◽

pp. S1432

Author(s):

D.A. Colevas ◽

K. Misiukiewicz ◽

A.T. Pearson ◽

J. Fayette ◽

J.R. Bauman ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13355993.791652823 ◽

2012 ◽

Author(s):

Marco Merlano

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13355993.14726100 ◽

2011 ◽

Author(s):

Jan Vermorken

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽